Didanosine Adjusted

For wt over 60 kg

Adjusts didanosine dosing based on renal impairment to prevent drug accumulation.

mg/dLumol/L
mg/dLumol/L
ml/minml/24hrL/24hr

Indications for Use

Used primarily for HIV‑1 infection when intolerance or failure of zidovudine occurs, with clinical benefit shown in randomized comparisons demonstrating improved CD4 counts and delayed clinical deterioration 1 [Level I evidence].

  • Utility: Provides alternative NRTI activity and maintains antiviral response in zidovudine‑pretreated patients 2 [Level II evidence].
  • Notes: Consider use when resistance, toxicity, or hematologic intolerance limits zidovudine.

Insights & Cautions

Adjust dosing downward in renal impairment due to reduced clearance and increased exposure 1 [Level II evidence]. Avoid tenofovir co‑administration because it increases didanosine levels and toxicity risk 2 [Level II evidence]. Monitor closely for pancreatitis and peripheral neuropathy, the most serious adverse effects 3 [Level II evidence].

Use on an empty stomach; avoid alcohol; high risk of lactic acidosis, hepatomegaly, and retinal/optic toxicity (ASHP Drug Compendium [Didanosine; AIDS Meds]).